Relationship of Cerebral Perfusion Pressure Variability to Sepsis-associated Encephalopathy
1 other identifier
observational
110
1 country
1
Brief Summary
The purpose of the study is to evaluate whether variability of CPP (cerebral perfusion pressure) is related to sepsis-associated encephalopathy and outcomes of patients with sepsis.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started May 2014
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
May 1, 2014
CompletedFirst Submitted
Initial submission to the registry
October 27, 2014
CompletedFirst Posted
Study publicly available on registry
November 11, 2014
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 1, 2015
CompletedStudy Completion
Last participant's last visit for all outcomes
March 1, 2017
CompletedNovember 6, 2017
October 1, 2017
10 months
October 27, 2014
October 31, 2017
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
relationship between cerebral perfusion pressure variability and sepsis-associated encephalopathy
To estimate CPP noninvasively, we will monitor the middle cerebral artery flow velocity of patients with sepsis using transcranial Doppler ultrasound in the first 72h of their enrollment. Diagnosis of a SAE was performed using the confusion assessment method for ICU(CAM-ICU).
cerebral perfusion pressure is assessed up to 72 hours
Secondary Outcomes (8)
Duration of mechanical ventilation
All the participants will be followed up until discharge or death, assessed up to 24 months
Time of ICU stay
All the participants will be followed up until discharge or death, assessed up to 24 months
Time of hospital stay
All the participants will be followed up until discharge or death, assessed up to 24 months
90-day mortality rate
All the participants will be followed up until 90 days after their enrollment or death
1-year mortality rate
All the participants will be followed up until 1 year after their enrollment or death
- +3 more secondary outcomes
Study Arms (2)
SAE
patient who develop encephalopathy in the progress of sepsis
non-SAE
patient who do not develop encephalopathy in the progress of sepsis
Interventions
Eligibility Criteria
all patients admit to the general ICU of an academic teaching hospital
You may qualify if:
- clinical symptoms of sepsis, severe sepsis and septic shock
- age over 18 years
You may not qualify if:
- preexisting Neurological diseases
- traumatic brain injury
- intracranial infectious disease
- severe hepatic or renal dysfunction
- ICU discharge Within 72 hours
- pregnancy
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Kang Yanlead
Study Sites (1)
Kang Yan
Chengdu, Sichuan, 610041, China
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- Director of Intensive Care Unit
Study Record Dates
First Submitted
October 27, 2014
First Posted
November 11, 2014
Study Start
May 1, 2014
Primary Completion
March 1, 2015
Study Completion
March 1, 2017
Last Updated
November 6, 2017
Record last verified: 2017-10